The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neumora Therapeutics Inc shares valued at $4,999,977 were purchased by Burow Kristina on Oct 27 ’25. At $2.61 per share, Burow Kristina acquired 1,915,700 shares. The insider’s holdings grew to 6,046,907 shares worth approximately $15.12 million following the completion of this transaction.
Also, ARCH Venture Partners XII, LLC purchased 1,915,700 shares, netting a total of over 4,999,977 in proceeds. Following the buying of shares at $2.61 each, the insider now holds 6,046,907 shares.
Before that, ARCH Venture Partners X, LLC had added 1,915,700 shares to its account. In a trade valued at $4,999,977, the 10% Owner bought Neumora Therapeutics Inc shares for $2.61 each. Upon closing the transaction, the insider’s holdings increased to 1,915,700 shares, worth approximately $15.12 million.
As published in a research note from Guggenheim on October 27, 2025, Neumora Therapeutics Inc [NMRA] has been rated up from a Neutral to a Buy and the price target has been revised to $14. Analysts at JP Morgan downgraded the stock from ‘”a Neutral”‘ to ‘”an Underweight”‘ outlook in a report released in mid September. As of April 02, 2025, BofA Securities has decreased its “Buy” rating to a “an Underperform” for NMRA. Earlier on March 10, 2025, William Blair downgraded its rating. Their new recommendation was “a Mkt perform” for NMRA stock which previously was a “an Outperform”.
Analyzing NMRA Stock Performance
On last trading session, Neumora Therapeutics Inc [NASDAQ: NMRA] plunged -3.47% to $2.5. The stock’s lowest price that day was $2.4, but it reached a high of $2.69 in the same session. During the last five days, there has been a surge of approximately 46.20%. Over the course of the year, Neumora Therapeutics Inc shares have dropped approximately -79.63%. Shares of the company reached a 52-week high of $2.86 on 01/07/25 and a 52-week low of $0.61 on 05/14/25.
Support And Resistance Levels for Neumora Therapeutics Inc (NMRA)
According to the 24-hour chart, there is a support level at 2.37, which, if violated, would cause prices to drop to 2.24. In the upper region, resistance lies at 2.66. The next price resistance is at 2.82. RSI (Relative Strength Index) is 67.70 on the 14-day chart, showing neutral technical sentiment.
Is Neumora Therapeutics Inc subject to short interest?
Stocks of Neumora Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 0.37 million shares to 6.79 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 6.42 million shares. A jump of 5.46% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.48 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.48.
Which companies own the most shares of Neumora Therapeutics Inc (NMRA)?
In terms of Neumora Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 8 in the next 12 months, up nearly 208.88% from the previous closing price of $2.59. Analysts anticipate Neumora Therapeutics Inc stock to reach 8 by 2025, with the lowest price target being 8. In spite of this, 3 analysts ranked Neumora Therapeutics Inc stock as Buy at the end of 2025. On March 07, 2025, Stifel assigned a price target of “a Hold” to the stock and downgraded coverage with a $2.
